Dean Harvey Co-Authors ABA Antitrust Law Section Comments to the FTC Workshop on “Non-Competes in the Workplace: Examining Antitrust and Consumer Protection Issues”

The American Bar Association Section of Antitrust Law recently submitted comments to the Federal Trade Commission in connection with the January 2020 FTC workshop on “Non-Competes in the Workplace: Examining Antitrust and Consumer Protection Issues.” In section two of the submission, Lieff Cabraser partner Dean M. Harvey provided detailed commentary on the “Impact of Non-compete

2022-09-21T16:37:37+00:00April 27th, 2020|Antitrust, Employment Law|

Judge Gives Preliminary Approval to $120M Settlement Deal For Drivers in GM Ignition Switch Defect and Injury Litigation

As reported by Law360 (subscription), U.S. District Judge Jesse M. Furman has issued an order granting preliminary approval to a $120 million settlement deal reached by plaintiff drivers with General Motors over vehicles that lost value from faulty ignition switches, finding that the deal is fair and that he will “likely

2022-08-10T17:24:39+00:00April 27th, 2020|Car Accidents & Recalls|

Lieff Cabraser Announces That Plaintiffs Substantially Defeat Motion to Dismiss California Bail Bonds Antitrust Litigation

First-of-its-kind class action antitrust case brought by Lieff Cabraser and Justice Catalyst Law, Public Counsel, the National Consumer Law Center, and Towards Justice alleging that insurance companies in California conspired to unlawfully inflate California bail bond premiums will move forward to discovery and trial On April 13, 2020, Judge Jon S. Tigar of the U.S.

2020-04-14T13:19:31+00:00April 14th, 2020|Antitrust|

Dean Harvey Speaks on the Challenges of Navigating No-Poach Agreements at 68th Annual ABA Antitrust Law Section Virtual Spring Meeting

Lieff Cabraser partner Dean M. Harvey recently participated in panel discussion on “No-Poach: Assessing Risk in Uncertain Seas” as a part of the American Bar Association’s 68th Annual Antirust Law Section Virtual Spring Meeting. The panel was presented by the Cartel & Criminal Practice and Trial Practice Committees and will be turned into a podcast along with

2020-04-09T18:23:24+00:00April 9th, 2020|Antitrust, Firm News|

$320M Wells Fargo Derivative Suit Settlement Granted Final Approval

U.S. District Judge Jon S. Tigar of the Northern District of California has issued an order granting final approval to a $320 million settlement that will end shareholders’ derivative litigation relating to Wells Fargo’s unfair sales practices and its widespread fake accounts scandal. Plaintiffs in the suit, including the Fire & Police Pension Association of

2020-04-08T13:45:41+00:00April 8th, 2020|Securities Fraud|

Civil Litigation and Other Alternatives to Criminal Prosecution Can Achieve the Kind of Institutional Reforms Victims Care About

By Lieff Cabraser Attorney Avery Halfon The cultural impact of Harvey Weinstein’s criminal conviction for felony sex crimes may be broader than any other in years. As the revelations of his abuse were the spark that ignited the #MeToo movement, his guilty verdict symbolizes a formal recognition of how much sexual

2021-06-28T18:42:57+00:00April 6th, 2020|Sexual Abuse|

Elizabeth Cabraser in Trial Magazine on Meaningful Settlements that Bring Justice for Clients and Society

The American Association for Justice’s April 2020 issue of Trial magazine “Finding Your Way” includes a new article featuring commentary from Lieff Cabraser partner Elizabeth Cabraser, wherein she discusses meaningful settlements she’s been involved in and gives advice to lawyers on negotiating terms in settlements that bring justice for both clients

2022-08-10T17:24:13+00:00April 3rd, 2020|Commentary, Firm News|

Zantac Ordered Off Store Shelves Over Cancer Risks

FDA mandates halt to distribution of ranitidine (Zantac) due to potentially carcinogenic contamination After previously warning consumers and doctors last September that it had found measurable amounts of the carcinogen NDMA (N-notrisodimethylamine) in samples of the widely-used heartburn medication Zantac, the U.S. Food and Drug Administration has now ordered manufacturers to immediately stop distributing all

2020-04-02T08:22:00+00:00April 2nd, 2020|Prescription Drug Injuries|

Title